Rebecca Li, PhD, is the CEO of Vivli and on faculty at the Center for Bioethics at the Harvard Medical School. Previous to her current role she was the Executive Director of the MRCT Center of Brigham and Women’s Hospital and Harvard for over 5 years and remains a Senior Advisor at the Center. She has over 25 years of experience spanning the entire drug development process with experience in Biotech, Pharma and CRO environments. She completed a Fellowship in 2013 in the Division of Medical Ethics at Harvard Medical School. She earned her PhD in Chemical and Biomolecular Engineering from Johns Hopkins University.
Archives: Team Members
Team Member
Julie Wood
Julie Wood is the COO at Vivli. She is responsible for Operations, including supporting members and researchers data archiving, access and analysis on the Vivli platform. She is also a Co-Chair of the NIH Generalist Repositories Ecosystem Initiative (GREI) Coopetition Working Group. Prior to joining Vivli, Julie served as the Head of Communications and External Affairs at the Cochrane Collaboration and the Director of Corporate Communications at Oxfam GB in addition to working for a Microsoft partner.
Amanda Skarlupka
Amanda Skarlupka is a Senior Program Manager for Vivli. She brings over 12 years of experience in pre-clinical and translational research, data management, and program management including providing strategic input and grants management for the National Institutes of Health. Amanda earned her Ph.D. in Infectious Diseases and her M.S. In Biostatistics and Epidemiology from the University of Georgia.
Prior to this role, Amanda was a Health Scientist Administrator and Presidential Management Fellow at the National Cancer Institute within the Division of Cancer Prevention. She oversaw the division’s initiation, development, and close-out of programs designed to build trans-disciplinary bridges between data scientists, oncologists, and federal agencies.
Sarah Sweet
Sarah is a Senior Clinical Research Manager at Vivli. She received a Bachelor of Science in Biomedical Science (BS) from Salem State University in 2015 and a Master of Science in Biotechnology, Bioinformatics (MS) from University of Maryland in 2022.
Prior to this role, Sarah has worked in a Molecular Biology laboratory as an Associate Scientist at Azenta Life Sciences. Most recently, she worked at a precision oncology company, Guardant Health, which specializes in liquid biopsy. Here, she served as a supervisor where she led Biospecimen management operation teams in the San Diego and Redwood City laboratories and gained experience in clinical trial sample management and clinical trial project coordination.
Subha Madhavan, PhD
Subha is a dynamic and results-driven leader with a strong track record of excellence in organizations that operate at the nexus of science, technology and business. She has initiated and successfully directed several productive clinical research and development programs at the Georgetown Lombardi Comprehensive Cancer Center, MedStar hospital network, FDA, NIH and BioPharma industry. She was co-leader of the FDA’s Center for Excellence in Regulatory Science and worked with the Oncology and Vaccine teams. She was an advisory member to the Biden Foundation’s Cancer Moonshot Program and advised on pre-competitive data sharing initiatives across Pharma, Health Tech companies and research organizations to drive innovation. She has been recognized for her work through several awards including the Service to America award in the Science and Environment category (2005), Research Acceleration Award by AACR and Pancreatic Cancer Action Network (2015), and Women in Tech Global award (2021). She is currently the Head of Clinical AI/ML & Digital Sciences at Pfizer worldwide R&D where she leads a team focused on advancing precision therapies across multiple treatment areas including Anti-Infectives, Oncology, Immunology & Inflammation among others.
Jessica Baker
Jessica Baker is a recent graduate of the Masters in Bioethics program at the Center for Bioethics, Harvard Medical School. Her studies include work in Research Ethics, Global Health Ethics, and the foundations of Bioethics. Prior to matriculating at Harvard, Jessica obtained a J.D. from Southern Methodist University Dedman School of law, as well as undergraduate degrees in English from Davidson College and Psychology from the University of Utah.
Jessica’s work at Vivli includes assisting in communications, policies and procedures, and governance issues, combining her interests in research ethics, public outreach, and the legal and regulatory frameworks of human subjects research.
Irene Troupansky
Irene Troupansky is the Senior Software Architect at Vivli.
Prior to joining Vivli, Irene was a Senior Software Architect at Examity where she helped the company to launch its first Cloud SaaS Multi-Tenant version of Examity Platform and lead its further design and development through the company rapid growing, insuring Examity’s leading place as online proctoring provider. Prior to Examity, Irene was a Lead Architect/Developer at Tracker Systems, where she helped the company to upgrade its product to a Cloud SaaS version and lead the product further design and development.
Mark Barnes, JD
Mark Barnes, J.D., law practice and his teaching at Yale focus on health care law and finance, human and animal research, stem cell and genetic research, research grants and contracts, research misconduct, and international research. Mr. Barnes formerly served at Harvard as the Senior Associate Provost and University Senior Research Officer and started and directed Harvard’s HIV/AIDS treatment programs in Nigeria, Tanzania and Botswana. He serves on the Ethics Working Group of the NIH’s HIV Prevention Trials Network (HPTN) and is the ethics advisor to HPTN Trial 071 in South Africa and Zambia. Mr. Barnes has held senior appointed positions in the New York City and State departments of health.
Justin McCarthy, JD
Justin McCarthy has over 27 years of experience in the pharmaceutical industry, with expertise in pricing, market access, global health policy, legal and compliance. In his most recent role, he led the Patient & Health Impact (PHI) team at Pfizer, one of the world’s premier innovative biopharmaceutical companies whose global portfolio includes medicines and vaccines. He led a team of experts in health economics and outcomes research, real-world data and analytics, patient-centered outcomes assessment, market access, pricing, strategy and contracting, to generate evidence of the value of Pfizer medicines and vaccines and negotiate with governments and payers around the world to ensure access for patients. He also formed a team to explore novel approaches to bring medicines to the market through innovative partnerships and payment models.
Previously, Justin led Pfizer’s Global Policy & International Public Affairs efforts, responsible for defining Pfizer’s public policy positions and advancing government and public affairs strategies internationally. Additionally, Justin was Chief Counsel for Pfizer’s Worldwide Research and Development division, advising on regulatory, licensing and clinical trial issues, and overseeing global intellectual property activities.
Justin serves as a health policy and market access advisor, and has previously served on the Secretary’s Advisory Committee for Human Subject Protection, Subcommittee on Harmonization
Nina M. Hill, PhD
Dr. Hill is an independent consultant and the former Vice President of Innovation Policy, Global Policy at Pfizer. She is a member of external advisory boards of the Multiregional Clinical Trials Center at Harvard and Brigham and Womens’ Hospital and Vivli. Her work at Pfizer addressed anti-microbial resistance, unmet policy needs in clinical trials, compassionate access, oncology, and vaccines.
Prior to joining Pfizer, as a director of the International Center for the Disabled she helped secure passage of the 1990 Americans with Disabilities Act. As a former leader of the March of Dimes in NYC, she worked to advanced maternal and infant health by advocating for expanded Medicaid coverage.
Holding a Ph.D. in Speech Science from Columbia University, she earned an MIT Certificate in Artificial Intelligence Business Strategies. She is a published author and graduate of the Executive Program, Columbia University Graduate School of Business and the Harvard Business School Pfizer Leadership Development Program.